Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.2052W HIGH $48.91
Volume
32.58 K
Value Traded
281.13 K
Short % Float
1.87%
Days to Cover
3.3
-3.85%Week
-15.87%1 Month
-20.09%3 Month
-65.82%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
87.23 M
EPS (TTM)
-0.14
P/E Ratio
-
Ent. Value
75.69 M
Total Shares
49.87 M
Float Shares
6.31 M
Insiders
87.33%
Institutions
4.40%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PLYX Catalyst Timeline
Dated clinical, regulatory and corporate events for Polaryx Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Polaryx Therapeutics, Inc.
10Total events
2Upcoming
1Tier-1 (high impact)
2025 to 2026Coverage
Upcoming catalysts 2
Event history 5
▲Fast Track DesignationPLX-200Designation
FDA Fast Track Designation for PLX-200 across all four indications
CLN2 disease, CLN3 disease, Krabbe disease, Sandhoff diseasesource ↗
●Trial RegisteredPLX-200Trial
SOTERIA registered on ClinicalTrials.gov
CLN2 disease, CLN3 disease, Krabbe disease, Sandhoff diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How PLYX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-02-06 | PLX-200 (newly formulated gemfibrozil) | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 58%
Micro Cap(rank 391 of 673)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PLX-200 Small moleculeNCT07740512 | Lysosomal Storage Disorders | Phase 2 | NOT YET_RECRUITING | 24 | Feb 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every PLYX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Yang Alex Keun MoDirector, Officer (Chief Executive Officer), 10% Owner | Buy | 88,453 24,233,249 held | $4.07 | 05/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PLYX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PLYX for Q2 2026. | ||||
PLYX Institutional Ownership Trends
PLYX Short Interest
Shares sold short, counted twice a month.
1.87%
Short % of Float
of tradable shares sold short
118.3K
Shares Sold Short
-17.5% vs prior count
3.3 Moderate
Days to Cover
trading days of normal volume to buy every short share back
35.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PLYX ranks across every disease it competes in
Competitive Position is a premium feature
See how PLYX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPLYX News
-PLYX
Sep 1, 2026Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
Polaryx Therapeutics has appointed Dr. Will Charlton as Chief Medical Officer, effective September 1, 2026. Dr. Charlton brings over 15 years of experience in rare disease and pediatric drug development, enhancing the company's clinical leadership. His appointment comes as Polaryx prepares for the initiation of the SOTERIA Phase 2 trial for its lead drug candidate, PLX-200, in Q4 2026.
Read more →-PLYX
Aug 25, 2026▲ +6.4%on this news
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
Polaryx Therapeutics is advancing its operational readiness for the SOTERIA Phase 2 basket trial, set to begin in the fourth quarter of 2026. The trial will evaluate the safety and efficacy of PLX-200 across four rare pediatric lysosomal storage disorders. Key elements such as FDA authorization and CRO engagement are in place, supporting the trial's initiation.
Read more →-PLYX
May 28, 2026▲ +21.5%on this news
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
Polaryx Therapeutics has successfully closed a $10 million private placement equity financing to support the upcoming Phase 2 SOTERIA trial for its lead drug candidate, PLX-200. The trial will evaluate the drug across multiple lysosomal storage disorder indications. With this funding, Polaryx aims to achieve key clinical milestones and extend its operational runway into 2027.
Read more →-PLYX
May 14, 2026Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards
Polaryx Therapeutics has been awarded two honors at the 2026 GHP Magazine Healthcare & Pharmaceutical Awards, recognizing its contributions to pediatric lysosomal storage disorders and rare neurodegenerative diseases. The awards underscore the company's innovative approach and commitment to improving patient care. Polaryx's lead program, PLX-200, is set to enter a Phase 2 trial, further advancing its mission.
Read more →-PLYX
Apr 23, 2026Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
Polaryx Therapeutics will participate in the NTSAD Annual Family Conference from April 30 to May 3, 2026. The event will allow Polaryx to connect with families and advocates in the rare disease community while sharing updates on its clinical programs. The company is advancing its lead drug candidate, PLX-200, through a Phase 2 trial aimed at treating multiple lysosomal storage disorders.
Read more →-PLYX
Apr 21, 2026▼ -7.5%on this newsshared move
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
Polaryx Therapeutics has received Fast Track Designation from the FDA for its drug candidate PLX-200, applicable to four rare pediatric lysosomal storage diseases. This designation aims to expedite the review process for therapies addressing serious conditions with unmet medical needs. The SOTERIA Phase 2 trial will assess PLX-200's safety and efficacy across these indications.
Read more →-PLYX
Apr 15, 2026Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
Polaryx Therapeutics has been awarded the 2026 Pinnacle Award for Excellence in Pediatric Care, recognizing its innovative approach to treating lysosomal storage disorders (LSDs). The company focuses on developing scalable therapies that address shared biological mechanisms, aiming to improve treatment options for children and their families. CEO Alex Yang emphasizes the need for effective, patient-centered solutions in this area.
Read more →-PLYX
Apr 1, 2026Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
Polaryx Therapeutics, a clinical-stage biotech firm, will participate in the 25th Annual Needham Virtual Healthcare Conference. The event includes one-on-one investor meetings from April 13 to 16, 2026, and a group presentation on April 16 at 10:15 a.m. ET. This participation highlights Polaryx's commitment to advancing its clinical development efforts.
Read more →-PLYX
Mar 17, 2026Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
Polaryx Therapeutics has received FDA Fast Track Designation for its drug candidate PLX-200, aimed at treating Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 disease). This designation will facilitate expedited review processes and enhance interactions with the FDA. The company plans to initiate the SOTERIA Phase 2 trial to evaluate PLX-200's safety and efficacy across multiple lysosomal storage disorders.
Read more →-PLYX
Mar 12, 2026▼ -19.3%on this newsshared move
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
Polaryx Therapeutics is enhancing its engagement with the Krabbe disease community through participation in two key events. The company will attend the 2026 Krabbe Translational Research Network meeting and the Putt-Putt to #CureKrabbe event. Additionally, Polaryx is advancing its SOTERIA trial for its lead candidate, PLX-200, aimed at treating multiple lysosomal storage disorders.
Read more →-PLYX
Feb 27, 2026Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
Polaryx Therapeutics celebrates Rare Disease Day by reaffirming its commitment to patients with rare pediatric lysosomal storage disorders (LSDs). The company is advancing the SOTERIA trial, which will evaluate the safety and efficacy of its lead candidate, PLX-200, across multiple LSDs. This initiative highlights the urgent need for innovative treatments in this underserved area.
Read more →-PLYX
Feb 17, 2026▲ +64.3%on this news
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
Polaryx Therapeutics has selected a contract research organization for its SOTERIA Phase 2 trial, which will evaluate the safety and efficacy of PLX-200 in treating various lysosomal storage disorders. The trial is set to begin in the first half of 2026, following FDA approval. This trial represents a significant step in addressing the needs of patients with rare pediatric disorders.
Read more →-PLYX
Feb 10, 2026▼ -24.1%on this news· ran to -59% by day 3
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
Polaryx Therapeutics presented encouraging preclinical data for PLX-200, an investigational therapy for Krabbe disease, at the 22nd Annual WORLDSymposium. The findings indicate that gemfibrozil can restore motor functions and increase lifespan in affected mice. The company is preparing to launch the SOTERIA trial to further evaluate PLX-200's efficacy and safety across multiple lysosomal storage disorders.
Read more →-PLYX
Feb 5, 2026▼ -28.9%on this news· ran to -80% by day 3shared move
Polaryx Therapeutics Welcomes New Members of the Board of Directors
Polaryx Therapeutics has appointed three new members to its Board of Directors, effective January 29, 2026. The new members, Dr. Mitchel Berger, Mr. Francis A. Braun III, and Dr. Charles Ryan, bring extensive expertise in various fields. Their addition comes as Polaryx prepares to advance its lead candidate, PLX-200, into a Phase 2 clinical trial, marking a significant milestone for the company.
Read more →-PLYX
Feb 3, 2026▼ -37.3%on this news· ran to -75% by day 3shared move
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
Polaryx Therapeutics is set to present late-breaking data on PLX-200 for Krabbe disease at the 22nd Annual WORLDSymposium. This data supports the upcoming SOTERIA trial, a Phase 2 study aimed at evaluating PLX-200's safety and efficacy across several lysosomal storage disorders. The trial is scheduled to begin in the first half of 2026 following FDA approval.
Read more →-PLYX
Feb 2, 2026Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”
Polaryx Therapeutics has announced that its shares will begin trading on the Nasdaq under the symbol 'PLYX'. This milestone is seen as a significant step for the company as it prepares to launch the SOTERIA Phase 2 trial for its lead drug candidate, PLX-200, targeting various lysosomal storage disorders. The trial is designed to assess the drug's safety and efficacy across multiple indications.
Read more →-PLYX
Jan 30, 2026Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq
Polaryx Therapeutics has received approval to list its common stock on the Nasdaq under the ticker symbol PLYX, with trading expected to begin on February 2, 2026. This listing aims to attract investors interested in the company's mission to develop therapies for rare pediatric lysosomal storage disorders. The company is also preparing to launch a Phase 2 trial for its lead drug candidate, PLX-200.
Read more →About Polaryx Therapeutics, Inc.
Headquarters140 EAST RIDGEWOOD AVENUE, PARAMUS, NJ, 07652
BIOPHARMAWATCH ELITE PLUS
Trade the next PLYX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime